Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q4 2025 (December 31)11holders +4
6new positions
2sold out
$1.74avg. 13F price*
At the end of Q4 2025, 11 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, up 4 from Q3 2025. 6 opened new positions and 2 sold out. The largest holders were Amundi ($7.4M), BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($7.0M) and State of Wisconsin Investment Board ($4.4M).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $18.0M |
| Exits | 2 | $1.4M |
All 13F filers, Q3 2025 → Q4 2025: 9,788,924 shares bought and 856,000 shares sold, net +8,932,924 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 11 holders
| Amundi | 0.00% | New | 5,000,000 | $7.4M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | New | 4,750,000 | $7.0M |
| State of Wisconsin Investment Board | 0.01% | No change | 3,000,000 | $4.4M |
| Loomis Sayles & Co. L P | 0.00% | New | 9,043 | $3.6M |
| Sei Investments Co. | 0.00% | No change | 251,000 | $369K |
| Oppenheimer Asset Management Inc. | 0.00% | Reduce -1.2% | 82,000 | $121K |
| Stephens Inc. | 0.00% | No change | 24,000 | $35K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | Add +60.3% | 20,954 | $31K |
| NewEdge Advisors, LLC | 0.00% | New | 10,000 | $15K |
| MML Investors Services, LLC | 0.00% | New | 10,000 | $15K |
| CoreCap Advisors, LLC | 0.00% | New | 2,000 | $3K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.